Larimar Therapeutics ($LRMR): Can a Frataxin Replacement Win Approval on a Surrogate?

Scenarios

Bull case — the surrogate holds and the review moves

The agency accepts frataxin measured in skin as a surrogate reasonably likely to predict clinical benefit, files the rolling application for review when the last module lands in the second half of 2026, and approves on that basis with a broad label covering adults and children. If applicable eligibility conditions are met, a rare pediatric disease priority review voucher could provide an additional financing option. Designation alone does not award a voucher. The confirmatory Phase 3, now recruiting, reads positively in 2029 and converts the accelerated approval into a traditional one. On this path the mid-2027 launch target holds, the appointment of a commercial president in September 2026 pays off in field execution, and the need for further equity could be reduced if product receipts or a qualifying voucher transaction arrive in time.

Base case — approval is possible, timing and breadth are not

The application is accepted for review but the agency asks for more: a narrower label, a managed safety protocol for anaphylaxis, or post-marketing commitments tied to the confirmatory trial that make the mid-2027 launch look aggressive. The Phase 3 starts in late October 2026 as the registry estimates but enrols slowly across five countries, and management raises capital again before any revenue appears. The product could still reach patients, but later and in a smaller population than the open-label data alone would suggest, and the equity trades on the pace of enrolment rather than on the science.

Bear case — the surrogate does not carry the file

The agency declines to treat skin frataxin as a reasonably likely surrogate, or the complete submission raises manufacturing questions in the module the company guided to the second half of 2026. The ten anaphylaxis events in 43 dosed participants, nine of them in previously exposed patients, weigh on the benefit-risk assessment for a chronic daily injection in a pediatric population. With the cash runway ending in the third quarter of 2027, no revenue and a common-share count that increased from 83.1 million to 103.9 million during H1 2026, the next financing happens at a lower price. A randomized functional study could become necessary before approval, and its estimated primary completion is July 2029.

These are conditional editorial scenarios, not probability estimates or company guidance. [5] [1] [2]

What would change the analysis

The main dependencies are tissue-frataxin interpretation, sustained clinical benefit, practical safety management and financing. Evidence can strengthen or weaken each independently.

• Regulatory feedback: an accepted filing, review questions, proposed label and the final decision would show how the FDA weighs the surrogate, exposure-response analyses and safety database. A rolling submission is not filing acceptance or approval. [5]
• Functional confirmation: randomized results that demonstrate durable benefit would be stronger evidence than a comparison with an external natural-history cohort. Failure on functional outcomes would challenge the clinical interpretation even if tissue frataxin increases. [2]
• Additional safety exposure: event rates in newly treated participants, treatment interruptions and withdrawals would show whether risk-management changes improve treatment continuity. Prior exposure is a descriptive subgroup, not proof of the cause of anaphylaxis. [1]
• Funding and execution: an announced transaction could extend runway; a completed BLA and confirmed first dosing would resolve near-term milestones. Q3 2027 runway guidance is an operating-plan estimate, not a guarantee of financing through launch. [1]

01 — The company

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company incorporated in Delaware, headquartered in Bala Cynwyd, Pennsylvania, and listed on the Nasdaq Global Market under the symbol LRMR. The registrant's own history runs through a merger with Zafgen, Inc. in May 2020, after which the combined company took the Larimar name and concentrated on a single platform: a cell-penetrating peptide technology designed to move proteins into cells and into mitochondria. The Securities and Exchange Commission filing history dates the operating losses to inception in 2016, and the accumulated deficit reached $434.8 million at December 31, 2025 [9].

Everything the company does today runs through one asset: nomlabofusp, formerly CTI-1601, a recombinant fusion protein of human frataxin and a cell-penetrant peptide, given by daily subcutaneous injection, developed for Friedreich's ataxia. There is no approved product, no product revenue and no second clinical-stage candidate in the registration path. The quarterly report for the period ended June 30, 2026 records zero revenue and describes the commercial build-out — hiring, market development and legal work for a launch the company targets for mid-2027 — as the reason administrative expenses rose to $6.4 million in the quarter [1].

The leadership structure is being expanded for potential commercialization. The board added a President and Chief Operating Officer effective September 29, 2026, following prior commercial roles at Esperion Therapeutics and Melinta Therapeutics. The agreement provides an initial $560,000 annual base salary, a $35,000 signing bonus and a target bonus of 40% of base salary. The inducement grant covers 800,000 option shares with an exercise price equal to the closing price on the effective date, plus 50,000 restricted stock units. Such hiring adds commercial experience but also fixed spending before regulatory approval and product revenue. [6]

The company describes itself as building toward the first potential therapy to address the underlying cause of Friedreich's ataxia in both pediatric and adult patients. That claim is a company statement about a candidate, not an approved indication: nomlabofusp has not been approved by any regulatory authority, and the accelerated approval pathway it is pursuing depends on an endpoint the agency has said it is willing to consider rather than one it has accepted in a final judgment.

02 — The disease

Friedreich's ataxia is a rare inherited neurodegenerative disorder, and the peer-reviewed literature describes its mechanism with unusual clarity. In about 96% of affected individuals the cause is homozygosity for a GAA trinucleotide repeat expansion in the first intron of the FXN gene; most remaining patients carry the expansion on one allele and another pathogenic FXN variant on the other. The expansion silences FXN transcription and lowers the mitochondrial protein frataxin, which in turn reduces iron-sulfur cluster biogenesis and mitochondrial ATP production and raises mitochondrial iron and oxidative stress [10] [11].

The cited study estimates prevalence at approximately 1 in 40,000–50,000 people of Western European descent, and it is the most common inherited ataxia. Onset is typically in childhood or adolescence, with progressive limb and gait ataxia, dysarthria and hypertrophic cardiomyopathy; the range extends from early childhood to late adulthood. Loss of motor capacity and wheelchair reliance typically follow 15 to 20 years after onset [12] [13].

Two features of the disease matter for how a therapy is judged. First, the proximal genetic defect reduces a mitochondrial protein, with downstream metabolic, degenerative and inflammatory consequences: restoring frataxin addresses the mechanism rather than a downstream response [11]. Second, progression is slow and measurable on validated scales — the modified Friedreich Ataxia Rating Scale (mFARS) is the standard clinical outcome measure — which makes natural-history cohorts unusually important for interpreting single-arm data. The Friedreich Ataxia Clinical Outcome Measures Study (FACOMS) is the longitudinal reference the field uses: in matched untreated comparators, mFARS worsened by 6.6 points over three years in the pooled population, against 3.0 points in the extension of the omaveloxolone trial; this matched population is a contextual example, not a universal annual progression rate [14].

The disease is systemic, and that shapes the delivery problem. Frataxin is an intramitochondrial protein; the tissues that matter clinically include dorsal root ganglia, heart and the central nervous system. Any protein-replacement strategy must cross the plasma membrane, escape endosomes and reach mitochondrial import machinery in those tissues — a delivery challenge the literature has flagged for years, including concerns about toxicity and immunogenicity of cell-penetrating peptide fusions and the efficiency of endosomal escape [15].

03 — Nomlabofusp

Nomlabofusp is a recombinant fusion protein combining human frataxin with a cell-penetrant peptide, designed to enter cells, reach mitochondria and release mature frataxin. Administration is subcutaneous; the current open-label study uses daily dosing [5] [16].

The mechanistic case is direct and, in the laboratory, consistent. In cell systems the frataxin delivered by nomlabofusp was detected in mitochondria of cardiac and neuronal cell lines and processed to mature frataxin across rat, human and mouse-derived lines, supporting cross-species mitochondrial delivery. In buccal swabs from participants in the Phase 1 study, mature frataxin increased after administration, with changes in gene expression consistent with intracellular pharmacodynamic activity [16]. Earlier work with a related TAT-frataxin fusion showed the approach can work in vivo: the protein transduced into mitochondria of patient-derived fibroblasts and, in a severe conditional mouse model, increased mean lifespan by 53% and improved cardiac output and aconitase activity [17].

The clinical program behind the current filing is a sequence of completed studies: single ascending dose and multiple ascending dose Phase 1 studies in adults, a four-week placebo-controlled Phase 2 dose-exploration study, an adolescent pharmacokinetic study, and the ongoing long-term open-label study. The dose in the open-label extension is 50 mg daily for adults, with weight-based equivalent dosing for adolescents [5].

The open questions the scientific literature keeps open are the ones that matter commercially. Delivery to the disease-relevant tissues is inferred from peripheral measurements, not measured in the central nervous system. The class-level concerns about chronic protein administration — immunogenicity, anti-drug antibodies and acute systemic reactions — apply to a daily injection intended for years of use. And the leap from raised tissue frataxin to slower neurological decline is a hypothesis the company's program is designed to support, not one the peer-reviewed record has yet established in a controlled clinical outcome study.

04 — The clinical data

The data package behind the accelerated approval request comes from the ongoing open-label study of daily subcutaneous nomlabofusp in adolescent and adult participants. The numbers below are the company's, released June 29, 2026 and repeated in the second-quarter report of August 4, 2026, with a June 2026 exposure and safety update and a March 2026 cutoff for the displayed tissue and functional analyses [5] [1]. [5]

Exposure. In the June 2026 update, forty-three adolescent and adult participants had received at least one dose and 22 remained, with a maximum treatment duration above 800 days. More than 10,000 doses had been administered. Thirteen adults had one year of treatment, seven had 18 months and three had two years. [5]

Biomarker. Skin frataxin levels rose after administration: 82% (9 of 11) of participants measured reached levels above the threshold comparable to asymptomatic carriers by six months, 100% (9 of 9) reached that threshold at one year, and 100% (3 of 3) maintained it through 18 months. The company frames these levels as comparable to those of asymptomatic heterozygous carriers, which is a biologically motivated reference, not a patient-specific guarantee of clinical benefit. [5]

Clinical scales. At one year, directional improvement was reported for mFARS and FARS-ADL (n = 13 each) and the nine-hole peg test (n = 12), against worsening on these measures in the FACOMS natural-history reference population. The Modified Fatigue Impact Scale also improved in the treated group (n = 13); no FACOMS fatigue comparator was available. [20] At one year the treated group showed a mean 1.0-point improvement in mFARS against a mean 1.6-point worsening in the reference group — a 2.6-point difference. Among participants who were non-ambulatory at baseline, one of six became ambulatory after one year; of the seven who were ambulatory at baseline, none progressed to non-ambulatory. [5]

At 18 months, the March 2026 analysis showed a mean mFARS change of −2.3 points in seven treated participants, compared with an estimated +2.3 points in the external natural-history reference: a calculated difference of 4.6 points. The reference value was interpolated from annual observations through three years using a linear equation, rather than measured at an 18-month visit. The apparent separation therefore combines a small open-label cohort with a modeled external comparator, not a randomized treatment effect. These seven functional assessments are distinct from the three participants evaluated for the skin-frataxin threshold at 18 months. [5]

How to read this. The comparison is between an open-label cohort and a separate natural-history population, not a randomised control. At one year, mFARS, FARS-ADL and fatigue analyses each included 13 participants, the nine-hole peg test included 12, and the biomarker-threshold analysis included 9; the 2.6-point difference is a cross-study comparison. The direction is consistent with the biomarker data and with the mechanism, and it is the evidence the agency reviewed when it said the existing data package appears capable of supporting submission and review — with approval a matter of review. The company also reported in August 2026 that additional participants were dosed in July and several adults and adolescents were in screening, so the exposure numbers move.

05 — Skin frataxin as a surrogate

The regulatory theory of this filing is that frataxin measured in skin is a surrogate endpoint reasonably likely to predict clinical benefit in Friedreich's ataxia. It is the single most important and least settled element of the case.

What supports it. Frataxin levels in accessible tissues differed significantly between group means, although individual values overlapped: in a validated non-invasive immunoassay, mean frataxin was 100% in controls, 50.2% in asymptomatic carriers and 20.9% in patients in buccal cells, and 100%, 75.3% and 32.2% respectively in whole blood; levels correlated inversely with GAA repeat length and directly with age of onset [12]. Longitudinal modelling published in 2026 found peripheral frataxin predicted age at symptom onset, age at loss of ambulation and long-term progression across cohorts, and argued explicitly for advancing frataxin's candidacy as a surrogate endpoint [18].

What remains open. The tissues that are easy to sample are not the tissues that cause the disease. A 2017 transcriptomic study of patient fibroblasts stated the caution directly: because those tissues are not directly involved in disease pathogenesis, their relevance as models of the molecular aspects of the disease is yet to be decided [19]. Frataxin isoform biology and extraction methodology complicate cross-study comparison, and the practical leap — that raising skin frataxin over weeks to months predicts slower neurological decline over years — has not been shown in a controlled clinical efficacy study. The same modelling paper calls frataxin a valid clinical biomarker and supports its candidacy; candidacy is not validation.

Where the regulator stands. After a Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot meeting, the agency signalled continued alignment with the use of skin frataxin to support an application seeking accelerated approval, and in the minutes of the multidisciplinary pre-submission meeting it reaffirmed willingness to consider frataxin as a novel surrogate and confirmed that the company's exposure-response analysis may support the submission. It also stated that the existing data package appears capable of supporting submission and review — and that approval will be a matter of review [8] [5]. Willingness to consider is a procedural position; the judgment on the complete file is the event.

06 — The FDA path

The regulatory timeline is compact and dated, and the dates matter more than the adjectives around them.

February 24, 2026. The agency granted Breakthrough Therapy Designation to nomlabofusp for the treatment of adults and children with Friedreich's ataxia, based on its review of available clinical data from the ongoing open-label study. The same announcement reported written communications after the START pilot meeting that continued to align with the use of skin frataxin to support a submission seeking accelerated approval, and reiterated the plan to submit in June 2026 [8].

June 29, 2026. Following minutes from a multidisciplinary Type B pre-submission meeting, the company submitted the first module of a rolling Biologics License Application. The minutes covered four points the company summarises: the existing data package appears capable of supporting submission and review of an application seeking accelerated approval, with approval a matter of review; the agency reaffirmed willingness to consider frataxin as a novel surrogate endpoint and confirmed the exposure-response analysis may support the submission; prospectively collected gene expression and lipid biomarker data may further characterise biological activity; and a rolling submission was agreed. The remaining modules, including the manufacturing module, are guided to the second half of 2026 [5].

The designations. The company's August 2026 corporate presentation lists Breakthrough Therapy Designation, START pilot participation, Rare Pediatric Disease Designation in the United States, Orphan Drug designation in the United States and the European Union, Fast Track in the United States, PRIME in the European Union and ILAP in the United Kingdom. It also states the expectation of eligibility for a rare pediatric disease priority review voucher if the product is approved [20].

What the path implies. Accelerated approval on a novel surrogate means the confirmatory trial is not optional decoration: it is the condition on which the approval rests. The company's plan aligns with that requirement — the company reported FDA alignment on having the confirmatory study underway at submission [21] — but it also means the confirmatory clinical risk extends to the estimated 2029 completion window, when the confirmatory trial is estimated to complete. The launch target of mid-2027 sits between the two.

07 — The confirmatory Phase 3

The planned confirmatory study is intended to verify clinical benefit if accelerated approval is granted. On the public trial registry it is NCT07778836: a global, double-blind, placebo-controlled study of subcutaneous nomlabofusp, 50 mg against placebo, in ambulatory participants, with 18 months of treatment in the company’s design and an estimated enrollment of 150. The registry lists sites at the University of South Florida, Northwestern, Clinilabs and UT Southwestern, and records the start date as estimated at October 26, 2026 with primary completion estimated at July 2029 [2].

Design, as the company presents it: roughly 100 to 150 participants aged 2 to 40 — opening at 12 to 40 and extending down to 2 years once the pediatric dose is confirmed — about two-thirds under 21, randomised 1:1, with upright stability as the primary outcome measure in the United States and mFARS in the European Union. All participants are expected to be ambulatory, which differs from the open-label cohort and narrows the population. Dosing is daily subcutaneous, self-administered or given by a caregiver. The company reported in May 2026 that the FDA considered change from baseline in the Upright Stability Score, a subscale of mFARS, a reasonable and clinically relevant primary endpoint [21] [20].

The eligibility criteria for NCT07778836, dated October 9, 2026, further narrow that population. Among the requirements are genetically confirmed GAA expansions on both alleles, an mFARS score of at least 20 but below 60 at screening and Day −1, and completion of the timed 25-foot walk within three minutes at each of those visits, with the usual assistive device if needed. Previous participation in a nomlabofusp trial is exclusionary when it involved signed consent and at least one dose of study drug, including placebo. Omaveloxolone is permitted subject to a stable dose and frequency for one year before screening. These conditions make the confirmatory population different from the open-label cohort, which included non-ambulatory and previously exposed participants. Permitting background therapy defines the treatment setting; it is not evidence of synergy or superiority over that therapy.

The timing gap. The company guided dosing of the first participant to the third quarter of 2026 in the June and August announcements. As of October 16, 2026, the company had not announced the dosing of the first participant; the registry's estimated start of October 26, 2026 falls in the fourth quarter. The registry date is an estimate, not evidence that dosing occurred. Recruiting status and a future estimated start can coexist because screening can precede treatment.

Why the design matters. An 18-month, two-arm study with functional primary endpoints is the evidence base the surrogate does not provide. Its readout — years away — is what determines whether the product's label and reimbursement position are built on a surrogate or on clinical outcomes. The enrollment target is small by cardiovascular or oncology standards and meaningful for a rare disease requiring ambulatory eligibility and long follow-up, The company planned sites in the United States, the European Union, the United Kingdom, Canada and Australia ; enrollment speed and retention therefore remain practical variables to watch.

08 — Safety: exposure, withdrawals and what remains uncertain

For a chronic daily injection, both acute reactions and the ability to remain on treatment matter. The June 2026 open-label update covered 43 dosed participants, 22 still in the study and more than 10,000 administered doses. These denominators describe the reported study population, not a randomized risk comparison. [5] [1]

Anaphylaxis: ten participants experienced anaphylaxis and discontinued. Nine had received nomlabofusp in a previous study; one of the eleven without previous exposure experienced an event. All affected participants responded to standard treatment and returned to their usual state of health without further sequelae. Previous exposure is important descriptive information, but the subgroup is too small and uncontrolled to establish why events occurred or predict an individual patient’s risk. [1]

Other discontinuations: three participants stopped after generalized urticaria; the company reported no new occurrences of that event after antihistamine therapy was initiated. Three stopped for other adverse events and five for reasons unrelated to treatment, primarily logistical. The total of 21 withdrawals includes all these categories. It is therefore inaccurate to treat every withdrawal as anaphylaxis or every logistical withdrawal as a drug-related event. [1]

Injection-site reactions and long-term dosing: the most frequent events were mild-to-moderate local injection-site reactions that decreased over time and did not cause withdrawals. Thirteen adults had one year of exposure, seven 18 months and three two years in the reported update. Longer observation among continuing participants is informative, while discontinuations mean those long-exposure groups are selected survivors of earlier treatment. [5]

Immunogenicity: published research on cell-penetrating frataxin delivery discusses toxicity, immunogenicity and endosomal escape as development challenges. That is a scientific rationale for monitoring, not a measured anti-drug-antibody incidence for the current clinical cohort. The report that urticaria stopped recurring after antihistamines cannot be generalized into proof that antihistamines prevent anaphylaxis. Updated safety denominators, uninterrupted exposure and protocol-specific risk management remain central to benefit-risk assessment. [15] [1]

Commercial consequence: a future label, monitoring requirements, training, restart procedures and treatment burden would affect how chronic subcutaneous treatment is delivered. These are conditional commercial considerations; the June data do not supply an approved regimen, a final label or a proven strategy that eliminates severe reactions.

09 — Competition and the standard of care

Omaveloxolone is an established reference point. The approved oral therapy activates the Nrf2 pathway and addresses downstream cellular stress rather than supplying frataxin. Its clinical evidence should be separated into the randomized pivotal study and the later extension analyses. In a propensity-matched comparison of the open-label extension against FACOMS, the primary pooled groups contained 136 participants each. At three years, mFARS worsened by 3.0 points in the treated extension group and 6.6 in the matched natural-history group: a difference of 3.6 points. This external-control analysis supports a slowing interpretation but is not a randomized three-year comparison. [14]

Protein replacement offers a different mechanism, not established superiority. Nomlabofusp aims to restore the deficient protein itself. The cell and early clinical tissue data demonstrate delivery and pharmacodynamic activity; they do not compare it head-to-head against the approved oral medicine. Differences in disease stage, ambulatory status, follow-up, concomitant treatment and analysis populations prevent ranking the two therapies by simply placing their numerical mFARS results side by side. [16] [5]

Gene and RNA approaches illustrate alternative delivery strategies. Published experimental work has delivered frataxin mRNA in lipid nanoparticles, producing mature protein in mouse liver after intravenous administration and detecting recombinant protein in dorsal root ganglia after intrathecal administration. Those preclinical findings establish neither clinical efficacy nor a timetable for market entry. Protein replacement can be repeatedly dosed and adjusted, while nucleic-acid approaches bring different questions about tissue targeting, duration, expression control and reversibility. [15]

The commercial hurdle remains substantial. A possible launch would require more than a mechanistic distinction: an approved population, practical safety management, a supply chain, reimbursement and willingness to accept daily injections. Management’s mid-2027 launch target is conditional on approval. The annual report identifies clinical, regulatory, manufacturing and competitive risks, and the Q2 report shows spending on commercial headcount and market-development activity before revenue. [9] [1]

Successful tissue-frataxin replacement and successful commercialization are separate propositions. Evidence of functional benefit, a manageable treatment experience and access to patients would be needed to connect them.

10 — Balance sheet and cash

The financial position at June 30, 2026, as filed in the Form 10-Q on August 4, 2026 [4].

Assets. Cash and cash equivalents $92.687 million plus marketable securities $63.580 million — $156.3 million together, against $136.9 million at December 31, 2025. Total assets $165.3 million.

Liabilities. Total liabilities $37.920 million: accounts payable $7.597 million, accrued expenses $25.367 million and operating lease liabilities $4.956 million in total. The balance sheet shows no line for borrowings, term debt or credit facilities. Operating lease obligations remain real liabilities even though they differ from interest-bearing borrowings.

Losses. Net loss was $32.8 million in the second quarter of 2026 against $26.2 million a year earlier, and $62.4 million for the first half. Research and development spending was $28.0 million in the quarter; administrative spending $6.4 million. For the full year 2025 the net loss was $165.7 million and the accumulated deficit $434.8 million at year-end [9].

Cash consumption, with its caveat. Operating activities used $88.6 million in the first half of 2026 against $45.9 million a year earlier. The cash-flow increase includes working-capital timing: the figure includes a $33.2 million decrease in accrued expenses alongside a $62.4 million net loss and $4.1 million of non-cash stock compensation. Read together: net loss and operating cash use measure different things. Neither can be divided into the June cash balance and presented as an assured runway.

The intervening quarter helps explain the funding trajectory: cash, equivalents and marketable securities totaled $200.4 million at March 31, 2026, following the February offering, before falling to $156.3 million at June 30. The May 14 update projected funding into Q2 2027, whereas the August 4 update projected Q3 2027. A lower reported balance and a later projected runway can coexist because one is a dated asset total and the other depends on the operating plan; the change in guidance is not new cash received. [21] [1]

Runway. The company projects cash into the third quarter of 2027. The 2025 annual report, filed before the second-quarter report, expected the balance and the February offering proceeds to fund operations into the second quarter of 2027; the August 2026 statement extends that by one quarter. Either way, the runway ends near the mid-2027 launch target and before the confirmatory trial reads out. The June 30, 2026 Form 10-Q, filed August 4, 2026, states that these conditions raise substantial doubt about the company’s ability to continue as a going concern and that additional capital is needed. This accounting disclosure is separate from management’s guidance that forecast operating expenses and capital expenditure can be funded into Q3 2027; it is not a declaration of insolvency. The company discusses additional equity, debt, royalty financing, collaborations and licensing among possible funding sources. [4]

11 — Capital structure

The share register has moved a great deal in twelve months, and every part of it is documented.

Common stock. 103,882,937 shares issued and outstanding at August 2, 2026, against 83,090,392 at December 31, 2025 and 63,815,065 at December 31, 2024 [4]. The first-half increase came from the February 2026 offering: 20,000,000 shares at $5.00, plus the underwriters' option over 3,000,000 more exercised in full on February 26, 2026 — 23,000,000 shares and net proceeds of about $107.6 million after discounts and expenses, [22] [23]. Authorized common shares rose from 115,000,000 to 215,000,000 during the same period.

Series A convertible preferred. Blue Owl Healthcare Opportunities IV exchanged 2,500,000 common shares for 250,000 preferred shares on December 16, 2025 and another 2,500,000 for 250,000 more on January 21, 2026 — 500,000 preferred shares outstanding at June 30, 2026. Each converts into 10 common shares, so the full position is 5,000,000 common shares on an as-converted basis, subject to a conversion blocker initially set at 9.99% of outstanding common that the holder may raise to 19.99% on 60 days' notice. The preferred carries no voting rights except as required by law and shares pari passu with common in a liquidation [24] [25].

Employee equity. 11,056,215 options outstanding at June 30, 2026 with a weighted-average exercise price of $5.83 — above the current market price — and 1,228,107 restricted stock units. The September 29, 2026 inducement grant added 800,000 options at that date’s closing price and 50,000 RSUs [6].

At-the-market facility. The quarterly report notes an at-the-market equity sales agreement with no sales reported through the June 30, 2026 quarterly filing. It is the standing dilution instrument: unused in that filing, potentially available if the runway needs extending before the launch. Taken together — 103.9 million common, 5.0 million as-converted preferred, 11.1 million options, 1.2 million RSUs and a disclosed ATM — current common shares, potential conversion shares, compensation awards and future financing capacity are separate categories.

12 — What to watch

The next twelve months decide most of the thesis. The items below are ordered by how much they move the outcome.

1. Completion of the rolling application. Guided to the second half of 2026, including the manufacturing module. Completion would allow the FDA to assess the full submission. Filing acceptance, review timing and any eventual action date remain separate milestones; a delay would add pressure to the conditional launch target.

2. First participant dosed in NCT07778836. Guided to the third quarter of 2026; the registry estimates an October 26, 2026 start. An announcement of first dosing closes the gap noted on this page; the enrolment curve over the following quarters is what determines whether a 2029 readout is realistic.

3. The agency's judgment on skin frataxin. Any advisory committee, briefing document or complete-response letter language on the surrogate is the single most informative event of the cycle.

4. Safety with more exposure. The open-label study keeps dosing. New anaphylaxis events, or a clean record among the newly enrolled participants without prior exposure, changes the benefit-risk picture in both directions.

5. Funding. With runway into the third quarter of 2027, the balance between remaining expenditure and available capital must be reassessed with each quarterly update. Further equity would dilute; a partnership might trade economics or rights for funding. A possible voucher depends on qualifying approval and cannot be treated as cash already received.

6. The reported quarter. The questions that matter in it: enrolment in both studies, cash at September 30, and any language on the submission completion.

Timing references derive from the August company update and the October trial-registry record; estimated dates remain estimates. [1] [2]

13 — Manufacturing, intellectual property and commercialization

The manufacturing module matters as much as the clinical narrative. The company expected to submit the remaining rolling-BLA modules during H2 2026, including chemistry, manufacturing and controls. The clinical dataset and the manufacturing package answer different questions: whether treatment can offer benefit is distinct from whether a product can be made consistently, tested, released and supplied at the required quality. A biologic can have encouraging pharmacodynamic data and still face manufacturing-review questions. [21] [1]

The annual report identifies reliance on third-party manufacturing partners for research, nonclinical and clinical supply, and the intended continuation of that reliance for commercial supply. That creates dependencies on outside capacity, quality systems and timely execution. The Q2 release makes the spending concrete: research and development expense included increased process-performance qualification and manufacturing work at third-party manufacturers, together with clinical, analysis, inspection-readiness and BLA-preparation costs. These are expenses incurred before an approved product generates sales. [9] [1]

The license stack contains ongoing economics. Note 8 of the June 2026 quarterly filing describes a transferable worldwide exclusive license from Indiana University, originally dated November 30, 2016, as amended. Consideration includes low-single-digit royalties on licensed-product net sales, development milestone payments up to $2.0 million in aggregate, sublicensing fees dependent on regulatory milestones, patent-expense reimbursement and a minimum annual royalty below $0.1 million. Those contractual obligations must be distinguished from hypothetical sales: a royalty rate is not revenue and a contingent milestone is not an amount already paid. [4]

A separate license with Wake Forest University Health Sciences expired in December 2025 with the last licensed patent under that agreement. That expiration does not mean the entire nomlabofusp intellectual-property estate expired. The 2025 annual report describes licensed composition-of-matter and method-of-use patents covering nomlabofusp in the United States and European Union with an indicated 2040 expiry, excluding possible extensions. It also discusses additional owned or co-owned applications. Granted patents, pending applications and possible extensions are separate forms of protection, and the filing expressly warns that applications may not issue or provide sufficient competitive protection. [9] [4]

Commercial preparation has a cost before it has a return. The Q2 release attributes higher general and administrative expense partly to commercial and related headcount, market development and readiness work. A launch would still require an approved label, access arrangements, inventory and a practical treatment pathway for daily injections. The new operating leadership appointment is consistent with preparing that infrastructure, but it does not establish regulatory approval or launch revenue. A narrow label or additional monitoring would change the size and cost of that infrastructure. [1] [6]

The important connection is financial: manufacturing qualification, confirmatory-study execution and commercial preparation can overlap. Management’s runway projection incorporates its operating assumptions, not a guarantee that every possible regulatory request or launch delay is covered. A favorable clinical interpretation does not by itself remove supply-chain risk; a sufficient manufacturing package does not by itself resolve benefit-risk. Both have to support the same eventual product. [9] [1]